197 related articles for article (PubMed ID: 22252014)
1. Chronic kidney disease in type 2 diabetes patients in France: prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes.
Detournay B; Simon D; Guillausseau PJ; Joly D; Verges B; Attali C; Clement O; Briand Y; Delaitre O
Diabetes Metab; 2012 Apr; 38(2):102-12. PubMed ID: 22252014
[TBL] [Abstract][Full Text] [Related]
2. Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how?
Haneda M; Morikawa A
Nephrol Dial Transplant; 2009 Feb; 24(2):338-41. PubMed ID: 19015168
[No Abstract] [Full Text] [Related]
3. Impact of sex and glucose-lowering treatments on hypoglycaemic symptoms in people with type 2 diabetes and chronic kidney disease. The French Chronic Kidney Disease - Renal Epidemiology and Information Network (CKD-REIN) Study.
Balkau B; Metzger M; Andreelli F; Frimat L; Speyer E; Combe C; Laville M; Jacquelinet C; Briançon S; Ayav C; Massy Z; Pisoni RL; Stengel B; Fouque D
Diabetes Metab; 2019 Apr; 45(2):175-183. PubMed ID: 29706470
[TBL] [Abstract][Full Text] [Related]
4. Use of complementary markers in assessing glycaemic control in people with diabetic kidney disease undergoing iron or erythropoietin treatment.
Konya J; Ng JM; Cox H; Cooke M; Lewis N; Bhandari S; Atkin SL; Kilpatrick ES
Diabet Med; 2013 Oct; 30(10):1250-4. PubMed ID: 23758176
[TBL] [Abstract][Full Text] [Related]
5. How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study.
Penfornis A; Blicklé JF; Fiquet B; Quéré S; Dejager S
Vasc Health Risk Manag; 2014; 10():341-52. PubMed ID: 24966684
[TBL] [Abstract][Full Text] [Related]
6. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
Sloan LA
J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
[TBL] [Abstract][Full Text] [Related]
7. Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes.
Scheen AJ
Diabetes Metab; 2019 Apr; 45(2):110-121. PubMed ID: 30477733
[TBL] [Abstract][Full Text] [Related]
8. Optimal medication dosing in patients with diabetes mellitus and chronic kidney disease.
MacCallum L
Can J Diabetes; 2014 Oct; 38(5):334-43. PubMed ID: 25284697
[TBL] [Abstract][Full Text] [Related]
9. Antidiabetic medication use in patients with type 2 diabetes and chronic kidney disease.
Rhee JJ; Han J; Montez-Rath ME; Kim SH; Cullen MR; Stafford RS; Winkelmayer WC; Chertow GM
J Diabetes Complications; 2019 Nov; 33(11):107423. PubMed ID: 31537413
[TBL] [Abstract][Full Text] [Related]
10. [Not Available].
Brøsen JMB; Bomholt T; Borg R; Persson F; Pedersen-Bjergaard U
Ugeskr Laeger; 2024 May; 186(20):. PubMed ID: 38808757
[TBL] [Abstract][Full Text] [Related]
11. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers.
Tong L; Adler S
Postgrad Med; 2018 May; 130(4):381-393. PubMed ID: 29667921
[TBL] [Abstract][Full Text] [Related]
12. Oral glucose lowering drugs in type 2 diabetic patients with chronic kidney disease.
Nogueira C; Souto SB; Vinha E; Braga DC; Carvalho D
Hormones (Athens); 2013; 12(4):483-94. PubMed ID: 24457396
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
Yale JF; Bakris G; Cariou B; Nieto J; David-Neto E; Yue D; Wajs E; Figueroa K; Jiang J; Law G; Usiskin K; Meininger G;
Diabetes Obes Metab; 2014 Oct; 16(10):1016-27. PubMed ID: 24965700
[TBL] [Abstract][Full Text] [Related]
14. National survey: Evaluation of cardiovascular risk factors in Thai patients with type 2 diabetes and chronic kidney disease after the development of cardiovascular disease.
Changsirikulchai S; Sangthawan P; Janma J; Sripaiboonkij N; Rattanamongkolgul S; Thinkhamrop B
Nephrology (Carlton); 2018 Jan; 23(1):53-59. PubMed ID: 27608176
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.
Nowicki M; Rychlik I; Haller H; Warren M; Suchower L; Gause-Nilsson I; Schützer KM
Int J Clin Pract; 2011 Dec; 65(12):1230-9. PubMed ID: 21977965
[TBL] [Abstract][Full Text] [Related]
16. Glycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidney disease - cross-sectional data from the German Chronic Kidney Disease (GCKD) cohort.
Busch M; Nadal J; Schmid M; Paul K; Titze S; Hübner S; Köttgen A; Schultheiss UT; Baid-Agrawal S; Lorenzen J; Schlieper G; Sommerer C; Krane V; Hilge R; Kielstein JT; Kronenberg F; Wanner C; Eckardt KU; Wolf G;
BMC Nephrol; 2016 Jun; 17(1):59. PubMed ID: 27286816
[TBL] [Abstract][Full Text] [Related]
17. Glycaemic, blood pressure and lipid goal attainment and chronic kidney disease stage of type 2 diabetic patients treated in primary care practices.
Corcillo A; Pivin E; Lalubin F; Pitteloud N; Burnier M; Zanchi A
Swiss Med Wkly; 2017; 147():w14459. PubMed ID: 28695552
[TBL] [Abstract][Full Text] [Related]
18. Glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with renal complications.
Huri HZ; Lim LP; Lim SK
Drug Des Devel Ther; 2015; 9():4355-71. PubMed ID: 26300627
[TBL] [Abstract][Full Text] [Related]
19. Assessment of markers of glycaemic control in diabetic patients with chronic kidney disease using continuous glucose monitoring.
Vos FE; Schollum JB; Coulter CV; Manning PJ; Duffull SB; Walker RJ
Nephrology (Carlton); 2012 Feb; 17(2):182-8. PubMed ID: 21883672
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial.
Satirapoj B; Watanakijthavonkul K; Supasyndh O
PLoS One; 2018; 13(10):e0206722. PubMed ID: 30379936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
